ReviewEmergency medicine clinics of North America2018
Community-Acquired Pneumonia.
Review in Emergency medicine clinics of North America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 99 citations in OpenAlex.
- A systematic review and meta-analysis of the efficacy and safety of glucocorticoids in the treatment of severe pneumonia.Clinics (Sao Paulo, Brazil) · 2025Pooled it
- Risk factors for drug-resistant pathogens in community-acquired pneumonia: systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- Article
- Therapeutic effect of eravacycline against carbapenem-resistant hypervirulentAntimicrobial agents and chemotherapy · 2026Article
- Evaluation of factors affecting Pneumonia Severity Index and antibiotic resistance status in culture-proven bacterial pneumonia.Frontiers in medicine · 2026Article
- Clinical outcomes in hospitalized patients with community-acquired pneumonia: A comprehensive analysis of associated factors.PloS one · 2026Article
- Omadacycline versus moxifloxacin for community-acquired bacterial pneumonia (OPTIC-2): a phase 3b, randomised, double-blind, multicentre, controlled, noninferiority trial.EClinicalMedicine · 2025Article
- The anti-inflammatory and antioxidant effects of astaxanthin as an adjunctive therapy in community-acquired pneumonia: a randomized controlled trial.Frontiers in pharmacology · 2025Article
- Multiplex droplet digital PCR for the detection and quantitation ofFrontiers in cellular and infection microbiology · 2025Article
- Prognostic value of the platelet, neutrophil, monocyte, basophil, and eosinophil to lymphocyte ratios in patients with severe community-acquired pneumonia (SCAP).Scientific reports · 2024Article
- A Review on Risk Factors, Traditional Diagnostic Techniques, and Biomarkers for Pneumonia Prognostication and Management in Diabetic Patients.Diseases (Basel, Switzerland) · 2024Review
- Use of Parenteral Antibiotics in Emergency Departments: Practice Patterns and Class Concordance.The western journal of emergency medicine · 2024Article
- Review
- A Study on the Etiology and Clinical Manifestations of Community-Acquired Pneumonia in Adults in Western India.Cureus · 2024Article
- Epidemiological and etiological characteristics of 1266 patients with severe acute respiratory infection in central China, 2018-2020: a retrospective survey.BMC infectious diseases · 2024Article
- Bacterial etiology of community-acquired pneumonia among adult patients in Ethiopia: A systematic review and meta-analysis.Heliyon · 2024Article
- Immunomodulatory Effects of Fluoroquinolones in Community-Acquired Pneumonia-Associated Acute Respiratory Distress Syndrome.Biomedicines · 2024Review
- Hyaluronic Acid is Associated with Severity and Prognosis in Patients with Community-Acquired Pneumonia.Journal of inflammation research · 2024Article
- Microbial variations in sputum cultures among hospitalized patients with community-acquired pneumonia: differences in sputum microbiota between asthma and COPD patients.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Community-acquired pneumonia is one of the most common infections seen in emergency department patients. There is a wide spectrum of disease severity and viral pathogens are common. After a careful history and physical examination, chest radiographs may be the only diagnostic test required. The first step in management is risk stratification, using a validated clinical decision rule and serum lactate, followed by early antibiotics and fluid resuscitation when indicated. Antibiotics should be selected with attention to risk factors for multidrug-resistant respiratory pathogens. Broad use of pneumococcal vaccine in adults and children can prevent severe community-acquired pneumonia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.